<DistDoc action="rep" dist="dist_id" distdocver="05.1" an="WSJO000020180322ee3m0012x" doctype="article"><SelectData><FolderName id="302210958" rl="100">WSJ</FolderName></SelectData><ReplyItem lang="en"><BaseLang value="en" fid="la"/><IPDocId fid="id">DA409AC9F5F3BBE8FF497FCF0A66610A SB11879568435714574337704584116824040693360</IPDocId><AccessionNo value="WSJO000020180322ee3m0012x" fid="an"/><Num value="890" fid="wc"/><Date value="20180322" fid="pd"/><Time value="101100" fid="et"/><SrcCode value="wsjo" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><TruncRules><XS value="27"/><S value="60"/><M value="78"/><L value="131"/></TruncRules><Title fid="hl"><SectionName fid="se">Business</SectionName><ColumnName fid="clm"></ColumnName><Headline fid="hd"><Para lang="en">No Revenue? No Problem—Hong Kong Draws Biotech Firms Looking to List; American startups like Moderna and Grail are among the dozens considering exchange as it loosens rules</Para></Headline></Title><Snippet><Para>Hong Kong's stock exchange is gearing up to allow biotechnology companies to sell shares before generating any revenue—and companies are preparing to rush in.</Para></Snippet><Byline fid="by">By Preetika Rana and Julie Steinberg </Byline><Credit fid="cr"></Credit><Copyright fid="cy">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright><CodeSets><CSet fid="co"><Code value="mdrthu"/></CSet><CSet fid="in"><Code value="i2569"/><Code value="i257"/><Code value="i951"/><Code value="i8150203"/><Code value="i81502"/><Code value="ialtinv"/><Code value="ifinal"/><Code value="iinv"/></CSet><CSet fid="re"><Code value="hkong"/><Code value="usa"/><Code value="asiaz"/><Code value="china"/><Code value="easiaz"/><Code value="namz"/><Code value="apacz"/><Code value="bric"/><Code value="chinaz"/><Code value="devgcoz"/><Code value="dvpcoz"/></CSet><CSet fid="ns"><Code value="c02"/><Code value="c14"/><Code value="c1711"/><Code value="ccat"/><Code value="m11"/><Code value="mcat"/><Code value="c1513"/><Code value="c15"/><Code value="c151"/><Code value="c17"/><Code value="c171"/><Code value="cactio"/><Code value="ncat"/><Code value="nfact"/><Code value="nfce"/><Code value="nfcpin"/></CSet></CodeSets></ReplyItem><MetadataPT><DocData><DocType value="article" fid="fmt"/><IPDocId fid="id">DA409AC9F5F3BBE8FF497FCF0A66610A SB11879568435714574337704584116824040693360</IPDocId><AccessionNo value="WSJO000020180322ee3m0012x" fid="an"/><Num value="890" fid="wc"/><Num value="4234" fid="cc"/><Date value="20180322" fid="pd"/><Date value="20180322" fid="upd"/><Date value="20180322" fid="md"/><Time value="101100" fid="et"/><Time value="101206" fid="upt"/><Time value="105759" fid="mt"/><BaseLang value="en" fid="la"/><Editor value="" fid="rve"/><RevisionNo value="5" fid="rvn"/></DocData><PubData><Restrictor fid="rst"><Code value="FSPNORMAWS0300"/><Code value="WSJO"/><Code value="fspFileId275519985"/><Code value="FUT"/><Code value="CLNTALL"/><Code value="CTGSMFS"/><Code value="CTGWSJ"/><Code value="DEEPWSJP"/><Code value="EN"/><Code value="IBNK"/><Code value="IFINAL"/><Code value="IINV"/><Code value="NAMZ"/><Code value="SFWSJ"/><Code value="TBAC"/><Code value="TBED"/><Code value="TBIZ"/><Code value="TBRK"/><Code value="TDJP"/><Code value="TDJWMNP"/><Code value="TFCDLIC"/><Code value="TFIN"/><Code value="TIAS"/><Code value="TIBMNB"/><Code value="TIMG"/><Code value="TINT"/><Code value="TIOP"/><Code value="TMNB"/><Code value="TMNBUS"/><Code value="TNPS"/><Code value="TNWP"/><Code value="TNWPN"/><Code value="TOPUSA"/><Code value="TSCH"/><Code value="TTRD"/><Code value="TTRK"/><Code value="TUSN"/><Code value="TWMSA"/><Code value="TYAS"/><Code value="TYLA"/><Code value="USA"/><Code value="fspWebpage"/><Code value="djrcef"/><Code value="MPCV1M9M1B1"/><Code value="MPCEnvPROD"/><Code value="MPCDocHash31F48AE204AC6197"/><Code value="FSPTHINGFINDER"/><Code value="FSP2YESCO"/><Code value="FSP2YESCOCOM"/><Code value="FSP2YESCOOC"/><Code value="FSP2YESCOCOMOC"/><Code value="FSPCATEGORIZER"/><Code value="FSPCATIN"/><Code value="FSPRBC"/><Code value="FSPRBCIN"/><Code value="FSP2YESIN"/><Code value="FSPRBCNS"/><Code value="FSP2YESNS"/><Code value="FSPCATRE"/><Code value="FSPRBCRE"/><Code value="FSP2YESRE"/><Code value="FSP2YESPEOC"/><Code value="FSPRBC611292"/><Code value="FSPRBC621478"/><Code value="FSPRBC648038"/><Code value="FSPRBC649439"/><Code value="FSPRBC703742"/><Code value="FSPRBC783012"/><Code value="FSPRBC799773"/><Code value="FSPRBC802123"/><Code value="FSPRBC803818"/><Code value="FSPRBC818182"/><Code value="FSPRBC829144"/><Code value="FSPRBC831127"/><Code value="FSPRBC831148"/><Code value="FSPRBC849536"/><Code value="FSPRBC849556"/><Code value="FSPRBC853402"/><Code value="FSPRBC857604"/><Code value="FSPRBC857605"/><Code value="FSPRBC860216"/><Code value="FSPRBC860346"/><Code value="FSPRBC860429"/><Code value="FSPRBC861005"/><Code value="FSPRBC861099"/><Code value="FSPRBC861199"/><Code value="FSPRBC861267"/><Code value="FSPRBC861461"/><Code value="FSPRBC861689"/><Code value="FSPRBC861790"/><Code value="FSPRBC861918"/><Code value="MPCCL"/><Code value="MPCJP"/><Code value="MPCKW"/><Code value="MPCKP"/><Code value="MPCESRE"/><Code value="MPCESIN"/><Code value="MPCESNS"/><Code value="FSP2AC"/></Restrictor><IPId value="DJENT" fid="ip"/><PublisherN fid="pub">Dow Jones &amp; Company, Inc.</PublisherN><AttribCode value="WSJO2" fid="atr"/><SrcCode value="WSJO" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><Logo img="wsjoLogo.gif" link="" src="http://logos.factiva.com"/></PubData><CodeSets><CSet fid="co"><Code value="mdrthu"><CodeD index="no" lang="en">Moderna Therapeutics Inc</CodeD><CodeI org="thingfinder" action="add"><CodeA name="db" value="ptf--aboutCo-00004106-20180321-231407.dictionary"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI></Code></CSet><CSet fid="in"><Code value="i2569"><CodeD index="no" lang="en">Biotechnology</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishIN_en_20180319140637"/><CodeA name="es_score" value="362"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="861790"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="829144"/><CodeA name="rule" value="703742"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="co:mdrthu"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="i257"><CodeD index="no" lang="en">Pharmaceuticals</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="802123"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="831127"/><CodeA name="rule" value="849536"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="i951"><CodeD index="no" lang="en">Health Care/Life Sciences</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861918"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="in:i2569"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="i8150203"><CodeD index="no" lang="en">Private Equity</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="649439"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="4"/></CodeI></Code><Code value="i81502"><CodeD index="no" lang="en">Trusts/Funds/Financial Vehicles</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="in:i8150203"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="ialtinv"><CodeD index="no" lang="en">Alternative Investments</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="in:i8150203"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="ifinal"><CodeD index="no" lang="en">Financial Services</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="in:i8150203"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="iinv"><CodeD index="no" lang="en">Investing/Securities</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="in:i8150203"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code></CSet><CSet fid="re"><Code value="hkong"><CodeD index="no" lang="en">Hong Kong</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishRE_en_20180319142019"/><CodeA name="es_score" value="198"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="861267"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="853402"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/><CodeA name="nodelevel" value="3"/><CodeA name="nodelevel" value="4"/></CodeI></Code><Code value="usa"><CodeD index="no" lang="en">United States</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishRE_en_20180319142019"/><CodeA name="es_score" value="100"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="861689"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="621478"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="asiaz"><CodeD index="no" lang="en">Asia</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861005"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="857604"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/><CodeA name="root" value="re:easiaz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="china"><CodeD index="no" lang="en">China</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861099"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/><CodeA name="nodelevel" value="2"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="easiaz"><CodeD index="no" lang="en">Eastern Asia</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861199"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="namz"><CodeD index="no" lang="en">North America</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861461"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:usa"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="apacz"><CodeD index="no" lang="en">Asia Pacific</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/><CodeA name="root" value="re:easiaz"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="bric"><CodeD index="no" lang="en">BRICS Countries</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="chinaz"><CodeD index="no" lang="en">Greater China</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="devgcoz"><CodeD index="no" lang="en">Emerging Market Countries</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="dvpcoz"><CodeD index="no" lang="en">Developing Economies</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:hkong"/><CodeA name="root" value="re:china"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code></CSet><CSet fid="ns"><Code value="c02"><CodeD index="no" lang="en">Corporate Changes</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860216"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c14"/><CodeA name="root" value="ns:c1711"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="c14"><CodeD index="no" lang="en">Stock Listings</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="611292"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c1711"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="c1711"><CodeD index="no" lang="en">Initial Public Offerings</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="799773"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="ccat"><CodeD index="no" lang="en">Corporate/Industrial News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="831148"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="857605"/><CodeA name="rule" value="803818"/><CodeA name="rule" value="849556"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c02"/><CodeA name="root" value="ns:c14"/><CodeA name="root" value="ns:c1711"/><CodeA name="root" value="ns:c1513"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="m11"><CodeD index="no" lang="en">Equity Markets</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860429"/><CodeA name="db" value="prbc---00018571-20180322-025042"/><CodeA name="rule" value="648038"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="mcat"><CodeD index="no" lang="en">Commodity/Financial Market News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860346"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:m11"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="c1513"><CodeD index="no" lang="en">Sales Figures</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="783012"/><CodeA name="db" value="prbc---00018571-20180322-025042"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="c15"><CodeD index="no" lang="en">Financial Performance</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c1513"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="c151"><CodeD index="no" lang="en">Earnings</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c1513"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="c17"><CodeD index="no" lang="en">Corporate Funding</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c1711"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="c171"><CodeD index="no" lang="en">Share Capital</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c1711"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="cactio"><CodeD index="no" lang="en">Corporate Actions</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c1711"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="ncat"><CodeD index="no" lang="en">Content Types</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c14"/><CodeA name="root" value="ns:c1711"/><CodeA name="root" value="ns:m11"/><CodeA name="root" value="ns:mcat"/><CodeA name="root" value="ns:c1513"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfact"><CodeD index="no" lang="en">Factiva Filters</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c14"/><CodeA name="root" value="ns:c1711"/><CodeA name="root" value="ns:m11"/><CodeA name="root" value="ns:mcat"/><CodeA name="root" value="ns:c1513"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfce"><CodeD index="no" lang="en">C&amp;E Exclusion Filter</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:m11"/><CodeA name="root" value="ns:mcat"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI></Code><Code value="nfcpin"><CodeD index="no" lang="en">C&amp;E Industry News Filter</CodeD><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:c14"/><CodeA name="root" value="ns:c1711"/><CodeA name="root" value="ns:c1513"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI></Code></CSet></CodeSets><DescTPC fid="de"><DescField fid="ipc">0388.HK 6540.OT 6540.YY GOOGL I/BTC JPM LLY M/HCR N/CHG N/MKT N/STK R/ASI R/CH R/FEO R/HK R/NME R/US SAN.FR SNY </DescField><DescField fid="ipd">WSJ WSJ.com WSJ.com Site Search WSJAsia WSJEurope WSJ Japanese Online WSJ-PRO-WSJ.com WSJSunday ASIA IPOS BIOTECH BIOTECH FIRMS HONG KONG STOCK EXCHANGE IPOS VC MA SB118795684357145743377045841168240406933601 Gates, Bill Lau, David Li, Charles Loncar, Brad PRO SYND WSJ-PRO-NP Venture Capital WSJ-PRO-VC CODES_REVIEWED Billion Dollar Startups VCBILLIONDOLLARSTARTUPS Exclusives VCEXCLUSIVES Life Sciences VCLIFESCINCES Asian Business News </DescField><DescField fid="ipcns">OASI </DescField><DescField fid="ipccodj">0388.HK GOOGL JPM LLY NDAQ SAN.FR </DescField></DescTPC></MetadataPT><ArchiveDoc xml:space="preserve"><Article markup="pp0" lang="en" index="field"><HandL fid="hlp"><Title fid="hl"><SectionName fid="se" index="field">Business</SectionName><ColumnName fid="clm" index="field"></ColumnName><Headline fid="hd"><Para lang="en">No Revenue? No Problem—Hong Kong Draws Biotech Firms Looking to List; American startups like Moderna and Grail are among the dozens considering exchange as it loosens rules</Para></Headline></Title><LeadPara fid="lp"><Para>Hong Kong's stock exchange is gearing up to allow biotechnology companies to sell shares before generating any revenue—and companies are preparing to rush in.</Para><Para>Dozens of early-stage drug makers and other biotech firms are planning to list in Hong Kong over the next two years, say executives, bankers and investors, as the exchange pushes through its <ELink type="webpage" ref="https://www.wsj.com/articles/listings-hungry-hong-kong-exchange-looks-to-loosen-rules-1519381124">biggest regulatory overhaul</ELink> in decades.</Para></LeadPara></HandL><TailParas fid="td"><Para>U.S. companies looking to go public include Moderna Therapeutics Inc., a Cambridge, Mass.-based startup that is considering a dual listing on Nasdaq and Hong Kong as early as next year, according to a person familiar with the company's plans.</Para><Para>Moderna earlier this year raised $500 million in a private financing round that <ELink type="webpage" ref="https://www.wsj.com/articles/moderna-therapeutics-valuation-nears-7-billion-1517536344">valued it at close to $7 billion</ELink>. The <ELink type="webpage" ref="http://www.wsj.com/articles/moderna-therapeutics-reveals-whats-in-its-billion-dollar-pipeline-1484051402">seven-year-old company</ELink> is <ELink type="webpage" ref="https://www.wsj.com/articles/startup-moderna-shows-promise-in-vaccine-trial-1493308801">testing vaccines</ELink> and experimental drugs designed to instruct the body's cells to produce proteins that could prevent and treat a host of diseases.</Para><Para>Grail Inc., a Menlo Park, Calif. company whose backers include billionaire Bill Gates and Alphabet Inc.'s venture-capital arm, is also planning a Hong Kong listing, according to a person familiar with the matter.</Para><Para>Grail, which hopes to develop blood tests for early-stage cancer detection, last year <ELink type="webpage" ref="https://www.wsj.com/articles/grail-acquires-cancer-tester-cirina-1496275920">merged with a Hong Kong-based startup</ELink> that claims to have developed such a test to detect a rare head and neck cancer.</Para><Para>Hong Kong Exchanges &amp; Clearing Ltd. is expected to finalize rules by late April that will allow biotech companies that have yet to generate any revenue or profit to list in the city, making it the second exchange after Nasdaq to do so.</Para><Para>The <ELink type="webpage" ref="https://www.wsj.com/articles/hong-kong-loosens-rules-to-attract-big-ipos-1513340469">looser requirements</ELink> would give early-stage biotech firms another option to raise funds to help pay for costly drug trials and research, and allow them to tap into a wider pool of investors—including those from China.</Para><Para>To be sure, there are significant risks for investors.</Para><Para>Buying into pre-revenue biotech companies can be a boom-or-bust proposition: For every company that turns out to be a success, there are many that end up failing. One concern is that Hong Kong is <ELink type="webpage" ref="https://www.wsj.com/articles/hong-kong-exchange-may-have-reached-its-peak-1520506743">inviting new listings</ELink> in a market that has relatively few institutional investors and brokerages specializing in biotech stocks.</Para><Para>Charles Li, the exchange's chief executive, acknowledged the potential pitfalls in an interview this week.</Para><Para>"The last thing we want to do is open up a new sector and have a big bust," he said. "Do I lose sleep? Yes, I do."</Para><Para>Still, he said he wants investors and companies to be in a position to reap potential outsized returns. Since 2010, the Nasdaq Biotech Index has returned 312%, compared with 143% for the broader S&amp;P 500, excluding dividends.</Para><Para>Mr. Li said the Hong Kong listings won't be a free-for-all. Pre-revenue biotech companies need to have successfully completed a phase-1 drug trial in order to list, among other requirements being discussed. Drug candidates are tested on humans over three phases.</Para><Para>Hundreds of industry executives, investors and bankers from the U.S., China and other countries gathered Thursday in Hong Kong at a biotech event organized by the exchange, with many others tuning in via a live stream.</Para><Para>David Lau, head of global investment banking for Hong Kong at JPMorgan Chase &amp; Co., said his bank has fielded inquiries from biotechs in mainland China, South Korea, Taiwan and the U.S. about listing in the city. Bankers expect offering sizes to span a few hundred million dollars on average.</Para><Para>The chief executive of China's Innovent Biologics Co. said the company, which is <ELink type="webpage" ref="https://www.wsj.com/articles/china-emerges-as-powerhouse-for-biotech-drugs-1491816607">developing two experimental cancer drugs</ELink> for Eli Lilly &amp; Co., is considering listing in Hong Kong or Nasdaq before the end of the year. It was valued at more than $1 billion in a recent financing round.</Para><Para>Hong Kong's opening up is also drawing companies that have been listed in other markets.</Para><Para>JHL Biotech Inc., which operates in mainland China and Taiwan, is deciding between a Nasdaq or Hong Kong initial public offering later this year, said people familiar with the matter. The company makes copies of existing biotech drugs and has licensed one to French drugmaker Sanofi SA.</Para><Para>JHL last month delisted from a stock exchange in Taiwan, where it had a market capitalization of about $465 million, according to S&amp;P Global Market Intelligence.</Para><Para>Nasdaq-listed Sorrento Therapeutics Inc., which is testing compounds for cancer and pain management and has a market capitalization of $708 million, last month said it's considering a Hong Kong listing. In a letter to shareholders, the <ELink type="webpage" ref="https://blogs.wsj.com/cfo/tag/sorrento-therapeutics/">company</ELink> pointed to two Chinese biotech firms that delisted from Nasdaq in recent years and later went public in Hong Kong, where they earned significantly higher market valuations.</Para><Para>Brad Loncar, chief executive of Kansas-based Loncar Investments LLC, said that if companies simply want to list in Hong Kong "to take advantage of the ongoing excitement and high valuations," it could be a recipe for problems down the road if markets turn.</Para><Para>Write to Preetika Rana at <ELink type="webpage" ref="mailto:preetika.rana@wsj.com">preetika.rana@wsj.com</ELink> and Julie Steinberg at <ELink type="webpage" ref="mailto:julie.steinberg@wsj.com">julie.steinberg@wsj.com</ELink></Para></TailParas><Byline fid="by" index="field">By Preetika Rana and Julie Steinberg </Byline><Credit fid="cr" index="field"></Credit><Contact fid="ct" index="field"></Contact><Notes fid="rf" index="field"></Notes><Art fid="art" index="field"></Art><Copyright fid="cy" index="field">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright></Article></ArchiveDoc><AdocTOC adoctype="article"><Item size="0" ref="distdoc:archive/ArchiveDoc::Article" type="arttext"></Item><Item size="0" ref="distdoc:archive/InvertText" type="invtext"></Item><Item subtype="primary" size="0" ref="https://www.wsj.com/articles/no-revenue-no-problemhong-kong-draws-biotech-firms-looking-to-list-1521713516" type="webpage"></Item></AdocTOC></DistDoc>

